MissionIR Articles

  • Elite Pharmaceuticals (ELTP) Presents at Rodman & Renshaw Conference

    Elite Pharmaceuticals, Inc. (OTCQB: ELTP) is a specialty pharmaceutical companydeveloping a pipeline of proprietary pharmacological abuse-deterrent opioid products and niche generic products. Elite specializes in oral sustained and controlled release drug products with high barriers…

  • Echo Therapeutics (ECTE) Presents at Rodman & Renshaw Conference

    Echo Therapeutics, Inc. (NASDAQ: ECTE) is changing the blood glucose monitoring industry. The company has successfully demonstrated the ability to continuously monitor blood glucose non-invasively in healthy, Type I, Type II and hospital patients. Echo’s…

  • DURECT (DRRX) Presents at Rodman & Renshaw Conference

    Biopharmaceutical company DURECT Corporation (NASDAQ: DRRX) has expertise in drug discovery, delivery and development, applying those skills primarily to therapeutics in the fields of pain management, CNS disorders, acute organ injury and metabolic diseases. The…

  • Dipexium Pharmaceuticals (DPRX) Presents at Rodman & Renshaw Conference

    Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) is a late stage pharmaceutical company focused on developing and selling Locilex (pexiganan cream 0.8%), a potent and broad spectrum topical antibiotic peptide, for the treatment of mild and moderate…

  • DiaMedica (DMCAF) Presents at Rodman & Renshaw Conference

    DiaMedica, Inc. (OTCQB: DMCAF) is a biopharmaceutical company focused on developing innovative treatments for stroke and other vascular diseases where no current therapies are available. The company is preparing to advance its proprietary recombinant form…

  • DelMar Pharmaceuticals (DMPI) Presents at Rodman & Renshaw Conference

    DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) is a clinical and commercial stage drug development company with a focus on the treatment of cancer. The company is in the midst of conducting clinical trials in the U.S.…

  • Delcath Systems (DCTH) Presents at Rodman & Renshaw Conference

    Delcath Systems, Inc. (NASDAQ: DCTH) is a specialty pharmaceutical and medical device company focused on oncology and, more specifically, the treatment of primary and metastatic liver cancers. The company’s proprietary product – Melphalan Hydrochloride for…

  • DBV Technologies S.A (DBVT) Presents at Rodman & Renshaw Conference

    DBV Technologies S.A. (NASDAQ: DBVT) is committed to finding a safe, effective and patient-friendly therapy for food and pediatric allergy patients, for whom there are no currently approved treatments. The company has a proprietary platform…

  • DARA BioSciences (DARA) Presents at Rodman & Renshaw Conference

    DARA BioSciences, Inc. (NASDAQ: DARA) is an oncology supportive care pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising…

  • CytRx (CYTR) Presents at Rodman & Renshaw Conference

    CytRx Corporation (NASDAQ: CYTR) is a biopharmaceutical research and development company specializing in oncology. CytRx is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic…

  • CytoSorbents (CTSO) Presents at Rodman & Renshaw Conference

    CytoSorbents Corp. (NASDAQ: CTSO) is a critical care immunotherapy company using blood purification to treat life-threatening illnesses. The company has developed a new hemoperfusion technology for removing toxins from the blood associated with sepsis, kidney…

  • CytoDyn (CYDY) Presents at Rodman & Renshaw Conference

    CytoDyn, Inc. (OTCQB: CYDY) is focused on developing new therapies that provide flexibility and freedom to people across the globe who are living with HIV. The company’s lead product, PRO 140, belongs to a new…

  • Cynapsus Therapeutics (CYNA) Presents at Rodman & Renshaw Conference

    Cynapsus Therapeutics, Inc. (NASDAQ: CYNA)  is a specialty central nervous system pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand turning ON of debilitating OFF episodes associated with…

  • Cymabay Therapeutics (CBAY) Presents at Rodman & Renshaw Conference

    Cymabay Therapeutics, Inc. (NASDAQ: CBAY) is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan…

  • Cyclacel Pharmaceuticals (CYCC) Presents at Rodman & Renshaw Conference

    Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Professor Sir David Lane, a…

  • Critical Outcome Technologies (COTQF) Presents at Rodman & Renshaw Conference

    Critical Outcome Technologies, Inc. (OTC: COTQF) is engaged in disease-specific drug discovery, optimization and pre-clinical development using a specially developed series of computer models. COTI is focused on the discovery and pre-clinical development of small…

  • Cortex Pharmaceuticals (CORX) Presents at Rodman & Renshaw Conference

    Cortex Pharmaceuticals, Inc. (OTC: CORX) has multiple drug development programs targeted toward the treatment of brain-related breathing disorders, such as obstructive or central sleep apnea and drug-induced respiratory depression. One key program involves the development…

  • CorMedix (CRMD) Presents at Rodman & Renshaw Conference

    CorMedix, Inc. (NYSE: CRMD) is a commercial-stage biopharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases. CorMedix’s first commercial product in Europe…

  • ContraVir Pharmaceuticals (CTRV) Presents at Rodman & Renshaw Conference

    ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV) operates as a biopharmaceutical company focused on developing targeted antiviral therapies. The company has two drug candidates in clinical studies. The first, FV-100, is now in phase III trials and…

  • CombiMatrix (CBMX) Presents at Rodman & Renshaw Conference

    CombiMatrix Corp. (NASDAQ: CBMX) is a clinical diagnostic laboratory specializing in cytogenomic testing for prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. As a full-scale cytogenetic and cytogenomic laboratory, CombiMatrix offers chromosomal microarray analysis, standard…